VELO3D announces Assure™ Quality Assurance and Control System for 3D metal printing and Stratasys Direct Manufacturing as First Customer of Assure
5.11.2019 18:00:00 EET | Business Wire | Press release
VELO3D, an innovator in metal Additive Manufacturing (AM) has announced the release and availability of the VELO3D Assure™ Quality Assurance and Control System for its Sapphire® 3D metal printers. Stratasys Direct Manufacturing, a subsidiary of Stratasys, Ltd. (NASDAQ: SSYS) and one of the largest providers of additive (3D printing) and conventional manufacturing services in North America, is the first customer to implement Assure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191105005695/en/
VELO3D’s Assure™ quality control dashboard enables engineers to track the quality and progress of Sapphire® machines in real-time. (Graphic: Business Wire)
Assure provides substantiation of part quality needed for volume production. It detects process anomalies, flags them, and highlights the corrective actions required so errors are not repeated. Through real-time, multi-sensor, physics-based detection algorithms, Assure delivers unprecedented traceability of part quality and flags process anomalies as soon as they occur. This decreases variation and provides comprehensive documentation to fast-track printed-part validation.
“Assure is a revolutionary quality-control system, an inherent part of the VELO3D end-to-end manufacturing solution for serial production,” says Benny Buller, founder and CEO of VELO3D. “Assure is part of our vision to provide an integrated solution to produce parts by additive manufacturing with successful outcomes.”
Stratasys Direct began working with VELO3D on Assure testing soon after they acquired a Sapphire printer earlier in the year. Stratasys Direct implemented Assure to identify variations and anomalies in the production of the parts on several builds. Throughout the study, Stratasys Direct accessed Assure’s dashboard and sophisticated algorithms to monitor the integrity of the builds, validate the bulk material density, observe ongoing process metrics, and verify the calibration of the system across multiple production runs. These trials and results confirmed the capabilities of the software, and were documented in a whitepaper that both VELO3D and Stratasys Direct co-authored which can be downloaded at https://info.stratasysdirect.com/rs/626-SBR-192/images/VELO3D_ASSURE_White_Paper_201911.pdf?utm_source=pr&utm_medium=release&utm_campaign=WEBREC-2019-WP-VELO3D-ASSURE
“Stratasys Direct has built a culture of continuous improvement that means we are continually setting new standards for our industry on quality,” said Kent Firestone, CEO of Stratasys Direct Manufacturing. “We integrated Assure into our quality control workflow because it produces highly actionable insights. The user interface features intuitive graphs and charts that enable us to see and interpret the vast amount of data collected during builds. This information helps our engineers verify the quality of the build each step of the way, and enables them to make quick decisions in the event of an issue. Assure helps us reduce production variation, improve yields, and circumvent anomalies to ensure consistent additive manufacturing.”
To learn more about Assure:
-
Stratasys Direct will host a webinar on November 14th at 10am PST; please visit this link to register:
https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=&eventid=2126421&sessionid=1&key=3925B221E06F51D08CE47106E3AD4F54®Tag=&sourcepage=register - VELO3D and Stratasys Direct will host a joint press conference at the VELO3D booth (Hall 11, E79) at formnext in Frankfurt, Germany on November 19 at 10 a.m.
About VELO3D
VELO3D empowers companies to manufacture anything. By bringing together innovations in software, hardware, and process control, VELO3D created the industry’s first SupportFree solution for 3D metal printing, enabling unlimited design innovation by reducing the need for support structures in metal additive manufacturing. The company’s Sapphire® system is built with a semiconductor mindset on quality assurance, ensuring repeatability and dependability throughout serial manufacturing. Headquartered in Silicon Valley, VELO3D helps companies deliver immediate business impact by making the impossible, possible. To learn more, please visit www.velo3D.com.
About Stratasys Direct
Stratasys Direct Manufacturing Inc. is the leading provider of 3D printing and advanced manufacturing services utilizing a broad range of additive and conventional technologies. We leverage nearly 30 years of 3D printing, design and engineering experience to ensure customers’ project success in each stage of product development, from prototypes to production runs. Serving companies of all sizes, from start-ups to established global brands, we develop methods, materials and processes that optimize and enhance additive and conventional manufacturing’s capabilities. Online at: www.stratasysdirect.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191105005695/en/
Contact information
VELO3D
Joyce Yeung
joyce.yeung@velo3D.com
972.914.8732
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
